Biomarkers of immediate drug hypersensitivity
Allergy · 2024
DOI: 10.1111/all.15933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, 2024. Verfasst von Cristobalina Mayorga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - IBIMA Plataforma BIONAND, Málaga, Spain. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institute of Health 'Carlos III' (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund), Andalusian Regional Ministry of Health, ISCIII thorough AES 2019 within the ERANET-EuroNanoMed-III framework (DrNanoDall project).
Abstract (Originalsprache)
Immediate drug hypersensitivity reactions (IDHRs) are a burden for patients and the health systems. This problem increases when taking into account that only a small proportion of patients initially labelled as allergic are finally confirmed after an allergological workup. The diverse nature of drugs involved will imply different interactions with the immunological system. Therefore, IDHRs can be produced by a wide array of mechanisms mediated by the drug interaction with specific antibodies or directly on effector target cells. These heterogeneous mechanisms imply an enhanced complexity for an accurate diagnosis and the identification of the phenotype and endotype at early stages of the reaction is of vital importance. Currently, several endophenotypic categories (type I IgE/non‐IgE, cytokine release, Mast‐related G‐protein coupled receptor X2 (MRGPRX2) or Cyclooxygenase‐1 (COX‐1) inhibition and their associated biomarkers have been proposed. A precise knowledge of endotypes will permit to discriminate patients within the same phenotype, which is crucial in order to personalise diagnosis, future treatment and prevention to improve the patient's quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - IBIMA Plataforma BIONAND, Málaga, Spain.
- Allergy Unit, Hospital Regional Universitario de Málaga-HRUM, Málaga, Spain.
- Allergy Department, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer - IDIBAPS, University of Barcelona, Barcelona, Spain.
- Department of Immunology, Allergology, Rheumatology, Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Medicine Department, Universidad de Málaga-UMA, Málaga, Spain.
ORCID-Profile: Cristobalina Mayorga, Adriana Ariza, Rosa Muñoz-Cano, Vito Sabato, Inmaculada Doña, Maria J Torres
Förderung
- Institute of Health 'Carlos III' (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (co-funded by European Regional Development Fund)
- Andalusian Regional Ministry of Health
- ISCIII thorough AES 2019 within the ERANET-EuroNanoMed-III framework (DrNanoDall project)
- Flemish Research Council
Zitieren
APA
Mayorga, C., Ariza, A., Muñoz-Cano, R., Sabato, V., Doña, I., & Torres, M. J. (2024). Biomarkers of immediate drug hypersensitivity. Allergy. https://doi.org/10.1111/all.15933
Vancouver
Mayorga C, Ariza A, Muñoz-Cano R, Sabato V, Doña I, Torres MJ. Biomarkers of immediate drug hypersensitivity. Allergy. 2024. doi:10.1111/all.15933
BibTeX
@article{Mayorga2024,
author = {Mayorga, Cristobalina and Ariza, Adriana and Muñoz-Cano, Rosa and Sabato, Vito and Doña, Inmaculada and Torres, Maria J},
title = {Biomarkers of immediate drug hypersensitivity},
journal = {Allergy},
year = {2024},
doi = {10.1111/all.15933}
}
EUVIMED